SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of antidiabetic medication that inhibit the absorption of glucose from the proximal tubule of the kidney and hence cause glycosuria. Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated hemoglobin by 0.5%–1.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function. More importantly, SGLT2i have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms underlying their cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+/H+ exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis. The main adverse events of SGLT2i include urinary tract and genital infections, as well as euglycemic diabetic ketoacidosis. Concerns have also been raised about the association of SGLT2i with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2-i improves the metabolic profile in patients with diabetes increasing glycosuria by inhibiting glucose reuptake in the renal proximal tubule. As a result, they induce a reduction of both arterial pressure and body weight, demonstrating impressive cardio- and nephro-protective effects [59].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 10×
“The EMPA-REG OUTCOME trial and the CANVAS program showed that the administration of Empa or Cana increased both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) when compared with placebo [65,68].”
BackgroundMethodResultInfluentialAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 5×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundInfluentialOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 14×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundMethodResultInfluential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 10×
“Results of DECLARE-TIMI, nevertheless, did not confirm a higher cancer risk with Dapa [69].”
BackgroundMethodResultInfluentialCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“Administration of Cana led to the reduction of end-stage renal disease, doubling of the serum creatinine level, or death from renal or CV causes [85].”
Background
Cited by
Items 201–300 of 325
Kim, Y., Jorge, A., Weber, B. N., & Costenbader, K. H. (2026) · Rheumatology · doi:10.1093/rheumatology/keag290 · Cited by 2
Infectious complications of newer agents in the fight against diabetes
Stover, K. R., Hugh, E., Sherman, J. J., Malinowski, S. S., Berdahl, G. J., & Riche, D. M. (2020) · The Nurse Practitioner · doi:10.1097/01.npr.0000718508.65708.a1 · Cited by 2
Bae, J., Kim, Y.-E., Lee, M., Lee, Y., Lee, B., Soo, B., & Kang, E. S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.6.539 · Cited by 2
“This class of ADDs has shown cardioprotective results in addition to the glucoselowering effects.(8) Since the mechanism of SGLT-2 inhibitors is quite different from previous ADDs, SGLT-2 inhibitors were expected to be effective not only as monotherapy but also in combination with other ADDs.”
BackgroundAntidiabetic agents: Do they hit the right targets?
Zhao, Y., Zhang, X., Liang, H., & Wang, L. (2022) · Frigid Zone Medicine · doi:10.2478/fzm-2022-0030 · Cited by 2
“Concerns have also been raised about the association of SGLT2 inhibitors with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury([171]).”
BackgroundYang, Y., Wang, X., Wang, Y., Xu, H., & Li, J. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03353-1 · Cited by 2
“SGLT2 inhibitors not only significantly reduce blood glucose levels but also improve islet beta-cell function and have a protective effect on cardiac muscle cells [33, 34].”
BackgroundKaur, P., Kotru, S., Tuteja, L., Ludhiadch, A., & Munshi, A. (2023) · Journal of Medical and Health Studies · doi:10.32996/jmhs.2023.4.4.20 · Cited by 2
Treatment Approaches and Challenges
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010005 · Cited by 2
Zhao, G., Wang, L., Fang, H., & Wang, L. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102526 · Cited by 2
Stability Indicating Assay of Empaglifozin and Metformin
Sahu, L. K., Si, S., & Patro, S. K. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00177 · Cited by 2
Al-Nimer, M. S. M., Latif, I. I., & Jawad, T. M. (2024) · Clinical Diabetology · doi:10.5603/cd.99395 · Cited by 2
“Among these pleiotropic effects are cardioprotection with empagli-flozin and the anti-inflammatory effect with sitagliptin [29, 30].”
Improving the solubility of pseudo-hydrophobic chemicals through co-crystal formulation
Janilkarn-Urena, I., Tse, A., Lin, J., Tafolla‐Aguirre, B. J., Idrissova, A., Zhang, M., Skinner, S. G., Mostowfi, N., Kim, J., Kalapatapu, N., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf007 · Cited by 4
Gajić, S., Janković, S., Stojadinovic, M. M., Filić, K., Bontić, A., Pavlović, J., Mrđa, I., Petrović, K., Hadži-Tanović, L., Žunić, J., et al. (2025) · Metabolites · doi:10.3390/metabo15040271 · Cited by 3
“Other authors, such as Tentolouris A. et al. [43], showed that SGLT2i treatment led to a small but statistically significant increase in Chol levels and a decrease in Tg levels.”
Effect of sodium-glucose cotransporter-2 inhibitors on renal handling of electrolytes
Meena, P., Bhargava, V., Bhalla, A. K., Rana, D. S., & Mantri, A. K. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-139348 · Cited by 2
SODIUM-GLUCOSE LINKED COTRANSPORTER 2 INHIBITOR: A NEW HORIZON IN THE TREATMENT OF TYPE-2 DIABETES
Bisht, R. (2021) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2021.v14i3.39667 · Cited by 3
“SGLT2-is, the newest class of oral antidiabetic agents, represent a therapeutic approach for treating T2DM that is independent of insulin secretion and activity.”
BackgroundInfluentialScoccimarro, D., Cipani, G., Dicembrini, I., & Mannucci, E. (2021) · Diabetes Care · doi:10.2337/dc21-0308 · Cited by 2
“Genito-urinary infections are more frequent in women, particularly those reporting previous recurrent episodes of such events (4).”
BackgroundAn Interesting Experience with Empagliflozin: Unidentified Body Odor
Uyaroğlu, O. A. (2021) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2021.554 · Cited by 2
Efecto cardioprotector de los inhibidores de sglt2 y agonistas del receptor de glp-1
Levette, J. A. N., Leal, F. J. V., Daza, O. P. R., Anturi, Y. C., Hernández, F. A. T., Benegas-Masi, A. J., Ortiz-Pérez, D. F., Villalobos, R. J. B., & Mora, J. F. P. (2022) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v6i4.2776 · Cited by 3
Yu, X., Wen, C., Xu, R., & Huang, W. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14662 · Cited by 2
Li, X., Yao, Y., Zhou, L., Yang, J., Chen, X., Zhang, C., Wang, M., Li, J., Li, B., & Xu, Y. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0009 · Cited by 2
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of glucose-lowering agents known for remarkable cardioprotective effects [7].”
BackgroundGaligutta, R. R., Hasik, P. N., Thomas, C., & Undela, K. (2024) · Endocrine · doi:10.1007/s12020-024-03925-x · Cited by 4
SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat
Vlachakis, P. K., Theofilis, P., & Tousoulis, D. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i11.669 · Cited by 2
Self-citationProposed mechanisms of systemic cardiovascular action of gliflosins
Zverev, Y. F., & Rykunova, A. Y. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf1915-22 · Cited by 1
Doğanay, B., & Çelebi, Ö. Ö. (2023) · Eskisehir Medical Journal Eskisehir City Hospital · doi:10.48176/esmj.2023.108 · Cited by 1
Pandey, R., Dwivedi, S., Hussain, M. S., Dixit, A. K., Sachan, A. K., Singh, S. K., & Arya, L. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i09.021 · Cited by 1
“Nonetheless, obesity is distinguished by elevated leptin levels resulting from the emergence of leptin resistance, and the levels of circulating leptin are directly correlated with the overall fat content within the body 8,10 .”
Parfianowicz, A., & Surma, A. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.78.57478 · Cited by 2
An overview of recent developments in clinical trials of anti-diabetic drugs
Madhuri, Y. B., Saifullah, Q., Pandey, M., & Bhattamisra, S. K. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05314-5 · Cited by 1
Nishimura, N., Miyake, M., Miyamoto, T., Ichii, D., Naoi, M., Narita, K., Kohashi, M., Tomioka, A., Torimoto, K., Kawashima, R., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15141824 · Cited by 1
Rashid, S. A., Prasad, M., Madar, I. H., Dhanabalan, K., Balasubramanian, R., & Maideen, N. M. P. (2025) · Current Drug Research Reviews · doi:10.2174/0125899775382225250811111859 · Cited by 1
Abuhashem, S., Aramin, M., Alhazmi, A. M., Hameed, A., Tom, L., Alshahrani, M. A., Alatawi, Z., Ibraheim, M. A., & Doraghi, K. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004669 · Cited by 1
“While initially designed to manage blood sugar levels in diabetic patients, SGLT2 inhibitors have broadened their application to treat congestive HF, irrespective of diabetes diagnosis or heart function [ 31 , 32 ] .”
Wang, T., Wang, T., & Zhang, R. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261447498 · Cited by 1
“46 Renally, SGLT2 inhibitors restore the tubuloglo-merular feedback mechanism by inhibiting sodium and glucose reabsorption in the proximal tubules, thereby increasing sodium delivery to the macula densa.”
SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review
Confederat, L. G., Pînzariu, A. C., Șerban, I. L., Condurache, M.-I., & Dragostin, O.-M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125224 · Cited by 2
“Similarly, empagliflozin demonstrated a HbA1c reduction of 0.85% after 24 weeks of treatment in monotherapy, 0.77% when added to metformin and 0.7% in patients on inadequately controlled basal insulin [22,30].”
InfluentialOrta, H., Aydın, C., Demirkıran, A., Perk, F., & Akyüz, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04398-8 · Cited by 1
“In one study, it was determined that PLT volume increased after epinephrine infusion [3, 19].”
The Impact of Carbohydrate Restriction and Nutritional Ketosis on Cardiovascular Health
Lowe, D. A., Corbit, K. C., & Weiss, E. J. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_5 · Cited by 1
Gupta, V., & Khurana, G. (2020) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20201102 · Cited by 1
“This may represent an inhibitory effect on the usual baroreflex-mediated increase in sympathetic tone that accompanies a decrease in BP.(22) In 2019, a meta-analysis by Piperidou reported that SGLT-2 inhibitors reduced systolic and diastolic blood pressure by 4.”
InfluentialPapazafiropoulou, A. K., Mpoumi, L., PAPANTONIOU, S. S., Rallatou, M., Antonopoulos, S., & Melidonis, A. J. (2021) · Annals of African Medicine · doi:10.4103/aam.aam_19_20 · Cited by 1
“[1] Empagliflozin, in addition to its anti-hyperglycemic effect, has a favorable profile in weight reduction, blood pressure (BP), and arterial stiffness.”
InfluentialMoparthi, K. P., Rushaidi, M. T. A., Muddam, M. R., Obajeun, O. A., Abaza, A., Jaramillo, A. P., Idris, F. S., Shaikh, H. A., Vahora, I., & Nath, T. S. (2023) · Cureus · doi:10.7759/cureus.44054 · Cited by 2
Nayudu, G. S. S., Benny, B. M., Thomas, G., Khan, M. A., & Basutkar, R. S. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_210_23 · Cited by 1
Sodium Glucose Cotransporter-2 Inhibitors: An Overview from Evolution to Clinical Implications
Ravi, R., Balasubramaniam, V., Dhingra, S., Murti, K., & Ponnusankar, S. (2024) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1292 · Cited by 1
Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Mesa 2: Insuficiencia cardíaca y diabetes mellitus tipo 2
Méndez, J., Martín, C. G., Remón, J., Houssay, S., Forte, E. H., Manfredo, S., Roselli, M., Ré, M., Hernández, D., Margossian, M., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.252 · Cited by 1
Mason, T. (2020) · TSpace (University of Toronto)
Hussain, S., Mustafa, A., Mumtaz, A., Shaheen, G., Qaiser, F., & Soban, M. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2115102800
Research Progress on the Protective Effect of SGLT2 Inhibitor on Kidney
姜, 玉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125569
Doğan, M. (2022) · Anatolian Current Medical Journal · doi:10.38053/acmj.1098603
Cabrera, I. K. R. (2022) · Repositorio Institucional (Pontificia Universidad Javeriana) · doi:10.11144/javeriana.10554.59403
Nguyễn, X. T. (2022) · Tập san Khoa học và kỹ thuật trường Đại học Bình Dương · doi:10.56097/binhduonguniversityjournalofscienceandtechnology.v5i2.49
Sousa, M. A. Z., & Schiabel, H. (2022) · doi:10.22533/at.ed.7392224064
Sánchez, G. A., Guillén, A. C., Calderón, V. H. A., Calderón, E. D. C. A., & Contreras, R. N. (2022) · doi:10.22533/at.ed.73922240619
ATENDIMENTO A USUÁRIOS DE CRACK EM UM CAPSAD DO MUNICÍPIO DE FORTALEZA: RELATO DE EXPERIÊNCIA
da Silva, I. A., Azevedo, A. K. D. S. O., Lopes, A. G. F., Pinheiro, D. R., Braga, E. D. A., Cruz, G. M. V., Benício, G. C., de Sousa, J. M., Freire, J. E. C., Silva, L. C. S., et al. (2022) · doi:10.22533/at.ed.7392224062
SÍNDROME DE BURNOUT ENTRE OS PROFISSIONAIS DE SAÚDE NO EXERCÍCIO DA PROFISSÃO
Andrade, G. S. P., Alves, L. F., Pereira, J. A., & Mariano, S. (2022) · doi:10.22533/at.ed.73922240618
RELATO DE UM CASO SOBRE UM PACIENTE JOVEM COM ACALÁSIA DA CÁRDIA
Silva, V. M. R., & Soares, A. A. B. D. S. (2022) · doi:10.22533/at.ed.73922240616
INSTRUMENTAÇÃO CIRÚRGICA EM PROSTATECTOMIA VIDEOLAPAROSCÓPICA ASSISTIDA POR ROBÔ
de Carvalho, A. T., Sordi, R. M., Matzenbacher, L. P. S., Lunardi, L. S., Gorreis, T. D. F., da Silva, F. G., Noro, A., de Cezaro, P., Wunder, A. P., Carcuchinski, A. P. N., et al. (2022) · doi:10.22533/at.ed.73922240610
MUCOSITE ORAL EM PACIENTES PEDIÁTRICOS SUBMETIDOS A TRATAMENTOS ONCOLÓGICOS: REVISÃO DE LITERATURA
Almeida, B. V. R. E., & Silva, L. T. (2022) · doi:10.22533/at.ed.73922240611
ANÁLISE EPIDEMIOLÓGICA DOS CASOS DE INFARTO AGUDO DO MIOCÁRDIO NA ÚLTIMA DÉCADA
Machado, N. D. O. F., Júnior, P. R. H., Francis, G. H. F., Costa, V. E. N., Telhada, A. A. C. M., Neto, R. M. B., Esteves, G. S., Côrtes, J. V. D. R., Bastos, R. M., & Côrtes, P. P. D. R. (2022) · doi:10.22533/at.ed.7392224066
Matos, A. C. D. M., Lima, G. M. R., & Santos, M. K. S. (2022) · doi:10.22533/at.ed.73922240620
MUDANÇAS DOS PARÂMETROS HEMODINÂMICOS EM PACIENTES COM CHOQUE CARDIOGÊNICO
Carmo, G. A. S., Faria, B. S. S. D. C., de Melo, A. B. F., dos Santos, V. L., Costa, G. E., Filho, M. B. D. B., Taniguchi, A. L. P., Alves, A. B. B., Silva, H. E. M. E., de Oliveira, A. B. C., et al. (2022) · doi:10.22533/at.ed.73922240612
Kusumawardani, D. R., Lestari, F., & Yuniarni, U. (2022) · Bandung Conference Series Pharmacy · doi:10.29313/bcsp.v2i2.4106
Payudis, A. N., Efremova, O. A., Камышникова, Л. А., Pavlovа, Y. S., Dudchenko, O. V., Khamnagadaev, I. I., & Голивец, Т. П. (2022) · The Clinician · doi:10.17650/1818-8338-2022-16-2-k656
Berezin, A. Е., & Berezin, A. A. (2022) · Vessel Plus · doi:10.20517/2574-1209.2021.141
The Heart in Diabetic Hypertensive Patients
Halabi, A., & Marwick, T. H. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_13 · Cited by 1
Heeba, G. H., Abolnaga, M., & Othman, E. M. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.301257
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review
Demir, M. E., Ercan, Z., & Erdoğan, B. (2023) · Journal of Cardiology & Cardiovascular Surgery · doi:10.51271/jccvs-0003
Mannucci, E., & Scoccimarro, D. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_23
Henry, S. M., & Strong, B. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69787-3.00107-6
Management and interplay of Type 2 Diabetes Mellitus with obesity
Hassan, A., Mohamed, N., Abdelhamid, A., Ahmed, H., & Abdelhaliem, N. (2023) · Sohag Medical Journal · doi:10.21608/smj.2023.223456.1397
Pulla-Urgiles, D. A., Jiménez, A. A. E., & Arteaga, M. P. J. (2023) · LATAM Revista Latinoamericana de Ciencias Sociales y Humanidades · doi:10.56712/latam.v4i2.1043
Low, S. K. M. (2022) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/171362
Canagliflozin produces a vasorelaxation effect on isolated rat thoracic aorta via NO/cGMP pathwaysPreprint
Tariq, M. S., Anjum, İ., Mushtaq, M. N., Barkat, K., Badshah, S. F., Ashraf, M. U., Malik, M. N. H., Jardan, Y. A. B., Nafidi, H., & Bourhia, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3508820/v1
Kale, N., & Dighe, P. R. (2023) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v11i2.1214 · Cited by 1
Uso de inibidores do cotransportador sódio-glicose 2 e sua relação com infecções geniturinárias
Pedrosa, D. F., Vilhena, D. V., Machado, A. M., Pinheiro, M. E. S., Mota, G. G., Vargas, E. J. C., Pereira, L. H. M. D., Andrade, S. O., Filho, F. R. P., Castro, P. E. S. D., et al. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-233
Review on sulphonamide analogues for the perspective of antibacterial and antidiabetic activity
Mittapalli, S. K., Saquib, & Mishra, A. (2024) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2024.19.2.0022 · Cited by 1
“These medications lower blood pressure and cause a slight reduction in weight [55-60].”
Empagliflozina y sus beneficios en la protección cardiaca: una revisión actualizada de la literatura
Delgado-Alcívar, S., Plúa, N. M., Pincay, A. M., Cedeño, C. B., Galarza, G. L., Ponce, K. B., Alcívar, K. D., & Alencastro, J. A. P. (2024) · Anatomía Digital · doi:10.33262/anatomiadigital.v7i3.1.3151
D’Haese, S. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20241014sh
Putra, W. E., Sustiprijatno, Hidayatullah, A., Widiastuti, D., & Heikal, M. F. (2024) · Iraqi Journal of Science · doi:10.24996/ijs.2024.65.8.1 · Cited by 1
“…that current SGLT2 inhibitors such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin have a promising future as antidiabetic drugs [20], these drugs require further evaluation or the identification of new drug candidates due to adverse effects such as acute kidney injury, bone…”
BackgroundAbdullah, K., Elsharkawy, M. M., Issak, E. R., ElSerafy, A. S., Idris, S., Bendary, A., Badr, H. R., Shehata, M., & Reda, A. (2024) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2024.159026
POR UMA PERSPECTIVA DA NEURODIVERSIDADE: UM DIÁLOGO ENTRE PSICOLOGIA, INFÂNCIA E EDUCAÇÃO INCLUSIVA
da Cruz, A. P., Gonçalves, M. M. B., Abreu, H. M. B. F., & Lacerda, H. C. (2024) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/978-85-7221-160-4.37
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2 · Cited by 1
As, A., Moscow, R. F., Pashkova, E. Y., Наильевна, В. Э., Lyamtseva, U. P., & Bedina, A. V. (2024) · Doctor Ru · doi:10.31550/1727-2378-2024-23-8-75-79
Empagliflozin Alleviates Sepsis-Induced Cardiac Inflammation Via the NF-κB Pathway
Fang, L., & Guan, W. (2024) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-025-03284-5
ElMerry, M. A., Abdellah, A. T., Soliman, M., Greash, M. A., & Nada, F. A. (2021) · International Journal of Health Sciences · doi:10.53730/ijhs.v5ns2.8599
Basile, P., Falagario, A., Carella, M. C., Dicorato, M. M., Monitillo, F., Santoro, D., Naccarati, M. L., Pontone, G., Ciccone, M. M., Santobuono, V. E., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061951
Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate
Shaikh, G. A., Yaqoob, S., Ayaz, A., Kumari, A., Molani, M. K., Azhar, A., & Nawaz, E. (2025) · Journal of Public Health and Community Medicine · doi:10.5455/jphcm.20250415090154
Rathour, M., Ahmad, J., Ahmad, F., Siddiqi, S. S., Pandey, V., & Sumedh, G. K. (2025) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_448_2024
Dubois, C., Minhas‐Sandhu, J. K., Alkabbani, W., Dyck, J. R. B., & Eurich, D. T. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100273
Aydın, C., Demirkıran, A., & Orta, H. (2025) · Angiology · doi:10.1177/00033197251365015
Sethi, B. K., Mehta, A., Dasgupta, A., Chawla, M. S., Deka, N., Agarwal, N., Mazumder, C., Ghosh, I., Gala, V., Muchhala, S., et al. (2025) · Cureus · doi:10.7759/cureus.99023
“Among currently available agents, empagliflozin demonstrates high selectivity for SGLT2 over SGLT1 (2500-fold) [11,14].”
Ling, A. W.-C., Chan, C.-C., Chen, S.-W., Kao, Y.-W., Huang, C.-Y., Chan, Y., & Chu, P.-H. (2020) · Figshare · doi:10.6084/m9.figshare.13203406
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574907
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574919
Wollnitza, S. (2023) · Dokumentenrepositorium der RUB (Ruhr University Bochum) · doi:10.13154/294-10554
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574922
Zhu, T., Ye, Z., Song, J., Zhang, J., Zhao, Y., Xu, F., Wang, J., Huang, X., Gao, B., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26367908
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574910
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574913
Yang, L. (2024) · D-Scholarship@Pitt (University of Pittsburgh)
Dinamično induciran transport vode preko membranskih koprenašalcev
Sever, M. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Rafeifadattis, K. F., Rizkillah, N., Aulia, N. N., Apriani, V., & Sudarjat, H. (2025) · Jurnal Ners · doi:10.31004/jn.v10i1.51869
Ханенко, О., & Popovych, Y. I. (2025) · Clinical & experimental pathology · doi:10.24061/1727-4338.xxiv.4.94.2025.10
Prevention and Treatment Strategies in Cardiovascular–Renal–Metabolic Syndrome
Tănase, D. M., Anton, I. B., & Gosav, E. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_17
Pereira, L., Filho, R. R. B. X., Freire, G. A., Martins, C. B. R., Perote, M. G. B., Campos, C. L. M., Monteiro, M. C. S. A., Maia, I. D. F. V. C., Lacerda, R. B., Gelves, L. G. V., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020829
“Sodium–glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin and em-pagliflozin lower blood glucose by promoting renal glucosuria and have demonstrated cardiovascular and renal benefits in large clinical trials [9–12].”
Influential
Metadata
- Authors
- Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-08-17
- Volume
- 16
- Issue
- 16
- Pages
- 2965
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC6720282
- OpenAlex
- W2967960051
- Cited by
- 300
- References
- 183
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 55 · 2023: 54 · 2022: 54 · 2021: 40 · 2020: 26 · 2019: 2
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, cardioprotection, renal protection, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glycosuria, HbA1c, arterial stiffness, endothelial function, Na+/H+ exchange, myocardial fibrosis, adverse events, lower limb amputation, acute kidney injury, cardiovascular risk
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Cardiotonic Agents, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.